PCH
ALLO icon

Polar Capital Holdings’s Allogene Therapeutics ALLO Stock Holding History

Polar Capital Holdings’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-251,473
Closed -$6.35M – 327
2020
Q4 		$6.35M Buy
+251,473
New +$8.2M 0.04% 236

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Polar Capital Holdings's ALLO Position: Q1 2021 in Review

Polar Capital Holdings sold out of Allogene Therapeutics (ALLO) in Q1 2021, closing a stake of 251,473 shares — an estimated $6.35M sold.

Polar Capital Holdings first reported a position in ALLO in Q4 2020 and held it in 1 quarter. The position peaked at $6.35M in Q4 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q1 2021.

  • Polar Capital Holdings reported no remaining Allogene Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Polar Capital Holdings sold 251,473 Allogene Therapeutics shares in Q1 2021, an estimated $6.35M.
  • Polar Capital Holdings first reported a position in Allogene Therapeutics in Q4 2020 and held it in 1 quarter.
  • Polar Capital Holdings's Allogene Therapeutics position peaked at $6.35M in Q4 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2021.

Based on Polar Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.